Sandbox Reserved 190

PPT-1

spinqualitylabelsall models HDSF Binding Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Anything in this section will appear adjacent to the 3D structure and will be scrollable. This is a default text for your page Sandbox Reserved 190 Inhibitors of PPT-1 PPT-1 is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. Hexadecylsulfonylfluoride (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 by binding to PPT-1. Unlike other inhibitors, HDSF is able to fit in the narrow, hydrophobic groove of PPT-1 leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will bind to SER-115 in the active site of PPT-1 via a sulponylation reaction and thus will inhibit the actions of PPT-1. Disease Associated With PPT-1 Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the 1p32 chromosome have been identified to cause INCL. Mutations Associated with INCL Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75. Common Mutation associated with JNCL and LINCL involve mutations Far Away From Active Site (Bellizzi J.  Widom J. Kemp.  Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578) Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased. (Dawson G. Schroeder C. Dawson P. 2010.  Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.) HDSF by binding to PPT-1 HDSF is able to fit in the narrow, hydrophobic groove of PPT-1 binds to SER-115 in the active site of PPT-1 bind to SER-115 in the active site of PPT-1 HDSF with Ser-115 TextToBeDisplayed